Reddit: MixedAttention: Elevated

Community Take (7D)

AstraZeneca's ENHERTU approval raises skepticism about OS's discount, with concerns about the Canadian micro-cap market. Investors should approach with caution.

The Story

News Summary

AstraZeneca's ENHERTU approved

Key Events

May 15:AstraZeneca and Daiichi Sankyo's ENHERTU receives FDA approval.

Sentiment: 70% bullish / 30% neutral (early) → 70% bullish / 30% neutral (late)

Impact: The narrative progressed from regulatory approval to expectations of market impact and sales potential.

Analyst ConsensusHold (21 analysts)

Target: $24 avg (+2% upside)

7 Buy · 13 Hold · 1 Sell

Signal

Bullish

Confidence

50%

Based on curated news sources (not retail comments)

Over the last 7 days: The FDA approval could drive revenue growth for ENHERTU, with no significant risks mentioned.

SentimentCautious Optimism

AnalysisHype

Bullish Factors

✓FDA approval for AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant treatment

Risk Factors

No bear risks identified

Analyst target

2% upside · $24–$25 range

▲ $24

Earnings

EPS: $0.29 → $0.45 (2026 vs 2027)

▲ Expected to grow 56%

Insiders (90d)

0 buys, 4 sells

Last: SELL Mar 17· 72d ago

▼Net selling $1.6M

Explore

$OS

Community Take (7D)

Key Events

Bullish Factors

Risk Factors

$OS

Community Take (7D)

Key Events

Bullish Factors

Risk Factors